Project Grant R01HL176323
Award Date
8/20/24
Completion Date
5/31/28
Dollars Obligated
$2.3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), is focused on understanding the mechanisms underlying HIV-associated hypertension and cardiovascular disease. The $641,960 award, granted to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences), will fund research to investigate how HIV-derived proteins, specifically the Tat protein, contribute to the development of...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) at the National Institutes of Health will support research to determine the pathophysiological mechanism and potential therapeutic approaches for alleviating HIV-associated chronic obstructive pulmonary disease (COPD). The total award amount is $1,405,336 over the project period from September 1, 2024 to May 31, 2028. The primary focus is on investigating how HIV and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program for Cardiovascular Diseases Research (CFDA 93.837), provides $123,104 to Emory University to conduct research on factors contributing to cardiovascular disease (CVD) comorbidities in persons living with HIV (PWH). The key objectives are to: 1) assess relationships between the metabolome, lipidome, HIV reservoir, and subclinical CVD, analyzing differences by sex; and 2) determine...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $100,558 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Stellenbosch University in South Africa. The grant, effective September 11, 2024 through August 31, 2029, will fund a series of prospective, multimodal cardiovascular research studies. The research aims to explore the underlying mechanisms of cardiovascular disease (CVD) in people living with HIV, characterize the impact of antiretroviral...
This federal Project Grant award of $771,902 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to examine the effects of HIV-associated extracellular vesicles (EVs) containing the protein NEF on macrophage heterogeneity and function, and their contribution to the formation of high-risk atherosclerotic plaques in people living with HIV. The research aims to identify novel mechanisms and therapeutic targets related to impaired...
This $394,723 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research by Texas Tech University Health Sciences Center (TTUHSC) to investigate the role of pulmonary arterial smooth muscle cells (PVSMC) as potential HIV reservoirs. The key objectives are to determine PVSMC's ability to support chronic HIV infection, spread the virus to immune cells during antiretroviral...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $249,000.00 to The University of Iowa to conduct research on "Mechanisms that Enhance and Suppress HIV-1 Resistance in Gene Edited Primary Human Cells." The project aims to develop a multi-factor gene editing strategy to modify hematopoietic stem and progenitor cells to enhance resistance against HIV-1 infection. The research will...
This $565,250 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a 5-year longitudinal study led by Duke University to characterize the effects of host-microbiome interactions on pulmonary function in a cohort of 500 adults with and without HIV in Botswana. The study will utilize advanced multi-omics techniques, including shotgun metagenomic sequencing, host...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,917,649 to the University of North Carolina at Chapel Hill to conduct research on HIV-associated lung disease. The project aims to characterize the nasal mucosal immune environment and microbiome of people living with HIV (PLWH) compared to seronegative individuals, and identify nasal mucosal endotypes associated with adverse pulmonary...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). The $491,056.01 award, effective May 20, 2025 through April 30, 2028, aims to examine the regulation and function of VPS34 in PAH, determine its impact on proliferation and survival of pulmonary artery...